What is the Ozempic lawsuit about?

Plaintiffs allege the manufacturers failed to adequately warn that GLP-1 receptor agonists can cause severe, sometimes long-lasting gastrointestinal injury and, in separate claims, non-arteritic anterior ischemic optic neuropathy (NAION) — a form of sudden, permanent vision loss. As of mid-2026, roughly 3,760 lawsuits are consolidated in two federal MDLs: gastrointestinal-injury claims in MDL 3094 (Eastern District of Pennsylvania) and NAION vision-loss claims in the newer MDL 3163. Bellwether (test) trial selection is expected in late 2026–2027.

What injuries are alleged in the Ozempic lawsuits?

Lawsuits allege gastroparesis (stomach paralysis), ileus / intestinal blockage, naion vision loss. These are allegations; a court has not found that Ozempic causes them.

Ozempic & GLP-1 Lawsuit

semaglutide / tirzepatide · Novo Nordisk · Eli Lilly · updated June 2026

GLP-1 drugs such as Ozempic and Wegovy face thousands of lawsuits alleging severe gastrointestinal injury (gastroparesis, intestinal blockage) and, in a separate federal case, permanent vision loss (NAION).

This page is general information about ongoing litigation and FDA safety actions — not medical or legal advice, and not a statement that Ozempic caused any injury. Allegations described here are claims that have not been proven in court. Always consult a licensed professional.

What the lawsuits allege

Plaintiffs allege the manufacturers failed to adequately warn that GLP-1 receptor agonists can cause severe, sometimes long-lasting gastrointestinal injury and, in separate claims, non-arteritic anterior ischemic optic neuropathy (NAION) — a form of sudden, permanent vision loss.

Gastroparesis (stomach paralysis)
Ileus / intestinal blockage
NAION vision loss

FDA action

In September 2023 the FDA added “ileus” (intestinal blockage) to the Ozempic prescribing information.

Where the litigation stands

As of mid-2026, roughly 3,760 lawsuits are consolidated in two federal MDLs: gastrointestinal-injury claims in MDL 3094 (Eastern District of Pennsylvania) and NAION vision-loss claims in the newer MDL 3163. Bellwether (test) trial selection is expected in late 2026–2027.

Frequently asked

What is the Ozempic lawsuit about?: Plaintiffs allege the manufacturers failed to adequately warn that GLP-1 receptor agonists can cause severe, sometimes long-lasting gastrointestinal injury and, in separate claims, non-arteritic anterior ischemic optic neuropathy (NAION) — a form of sudden, permanent vision loss. As of mid-2026, roughly 3,760 lawsuits are consolidated in two federal MDLs: gastrointestinal-injury claims in MDL 3094 (Eastern District of Pennsylvania) and NAION vision-loss claims in the newer MDL 3163. Bellwether (test) trial selection is expected in late 2026–2027.
What injuries are alleged in the Ozempic lawsuits?: Lawsuits allege gastroparesis (stomach paralysis), ileus / intestinal blockage, naion vision loss. These are allegations; a court has not found that Ozempic causes them.
Has the FDA acted on Ozempic?: In September 2023 the FDA added “ileus” (intestinal blockage) to the Ozempic prescribing information.

Our independent rating

Ozempic rating & details →Wegovy rating & details →

Sources